Aura Biosciences, Inc. (NASDAQ:AURA) CTO Sells $16,670.25 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 2,151 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $16,670.25. Following the sale, the chief technology officer now owns 209,456 shares of the company’s stock, valued at $1,623,284. This trade represents a 1.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Aura Biosciences Price Performance

Shares of AURA stock traded down $0.30 on Tuesday, hitting $7.65. 213,354 shares of the stock traded hands, compared to its average volume of 139,966. The firm has a market cap of $382.12 million, a price-to-earnings ratio of -4.42 and a beta of 0.29. The firm has a 50 day simple moving average of $8.07 and a two-hundred day simple moving average of $8.76. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Long Focus Capital Management LLC boosted its stake in shares of Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock worth $20,861,000 after acquiring an additional 1,404,228 shares during the period. Vanguard Group Inc. boosted its stake in Aura Biosciences by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock worth $15,764,000 after purchasing an additional 112,296 shares during the period. Franklin Resources Inc. grew its holdings in Aura Biosciences by 3.2% during the 4th quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock valued at $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in Aura Biosciences by 169.1% during the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after buying an additional 783,984 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Aura Biosciences by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after buying an additional 3,972 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AURA. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.